No Data
No Data
Jafron Biomedical: 2024 Interim Performance Forecast
Jafron BiomedicalLtd (SZSE:300529) Could Be Struggling To Allocate Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expand
A Look At The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Jafron BiomedicalLtd fair value estimate is CN¥24.00 Current share price of CN¥27.23 suggests Jafron BiomedicalLtd is potentially trading clo
Jafron Biomedical (300529.SZ) : Currently, all production capacity construction projects are being orderly carried out according to plan.
Jafron Biomedical (300529.SZ) stated on the investor interaction platform on June 19th that all production capacity construction projects of the company are progressing in an orderly manner according to the plan. At present, the company's production capacity can meet the development needs of its business, and the utilization rate of production capacity is in a reasonable range.
Jafron Biomedical (300529.SZ): specializes in research and development, production, and sales of biomedical materials and high-tech medical instruments.
Jafron Biomedical (300529.SZ) stated on the investor interaction platform on June 19 that the company specializes in the research and development, production and sales of biomaterials and high-tech medical instruments. Its main products, blood perfusion devices, mainly uses medical resin as an adsorbent to achieve specific adsorption of large-molecule toxins and protein-bound toxins in the blood. It is widely used in the treatment of uremia, poisoning, severe liver disease, multiple organ failure, etc., and can effectively save patients' lives or improve their quality of life.
Zhitong A Share Sale Restriction and Release List | June 3
According to the Zhitong Finance App, the ban on restricted shares of 31 listed companies was lifted on June 3, with a total market value of about 22.1 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Chinatungsten Gaoxin 000657, share incentives, limited sale and circulation 7206, Wanshilan Wei 600,60, the original shareholders placed and listed 248 million Huaguanghuanneng 600475 equity incentives to limit sales and circulation 7.753 million, Inner Mongolia Yiqi 600967 share incentives to limit circulation of 6.6331,000 Fangzheng Electric 002196 share incentives to limit sales and circulation of 10.495 million, Xinhua
No Data